A recombinant trivalent vaccine candidate against human adenovirus types 3, 7, and 55
A recombinant trivalent vaccine candidate against human adenovirus types 3, 7, and 55
复制标题
DOI：
10.1016/j.vaccine.2018.02.050
复制
发表时间：
2018-04-12
期刊：
影响因子：
5.5
通讯作者：
Zhou, Rong
中科院分区：
文献类型：
--
作者：
Liu, Tiantian;Zhou, Zhichao;Zhou, Rong
人腺病毒3型（HAdV-3）、7型（HAdV-7）和55型（HAdV-55）是儿童和成人急性呼吸道感染（ARI）的主要病原体。一种以上类型的HAdV可以同时感染患者，并且感染有时是致命的。然而，目前还没有批准用于儿童和成人的通用疫苗。因此，开发多价HMV疫苗以对抗HAdV感染变得势在必行。在这项研究中，我们构建了一种新的重组三价人腺病毒疫苗（rAdMHE 3-h55），它表达HAdV-55的六邻体蛋白在rAdMHE 3的E3区，以前制备的HAdV-3和HAdV-7的双价疫苗候选人。体外中和试验结果表明，rAdMHE 3-h55能诱导小鼠产生抗HMV-3、HAdV-7和HAdV-55的中和抗体。此外，用重组三价候选疫苗免疫完全保护分别用HAdV-3、HAdV-7或HAdV-55攻击的小鼠，显示出较低的肺病毒载量和较少的肺病理变化。目前的研究结果有助于开发一种新的腺病毒疫苗候选者，也促进了这种构建方法用于产生重组腺病毒疫苗。结论：重组腺病毒rAdMHE 3-h55对HMV-3、HAdV-7、HAdV-55攻击小鼠具有保护作用。未来优化这种候选疫苗的工作可能会导致一种更有效的方法来预防由普通人类腺病毒引起的呼吸道疾病。(C)2018爱思唯尔有限公司版权所有
Human adenoviruses types 3 (HAdV-3), 7 (HAdV-7) and 55 (HAdV-55) are major pathogens of acute respiratory infections (ARI) in children and adults. More than one type of HAdV can infect patients simultaneously, and the infections are sometimes fatal. However, there is currently no vaccine approved for general use in children and adults. Thus, development of a multivalent HMV vaccine to combat HAdV infection becomes imperative. In this study, we constructed a new recombinant trivalent human adenovirus vaccine (rAdMHE3-h55), which expresses the hexon protein of HAdV-55 in the E3 region of rAdMHE3, a previously prepared bivalent vaccine candidate against HAdV-3 and HAdV-7. The results of in vitro neutralization assays indicate that rAdMHE3-h55 can induce the production of neutralizing antibodies against HMV-3, HAdV-7, and HAdV-55 in mice. Furthermore, immunization with the recombinant trivalent vaccine candidate completely protected the mice challenged with HAdV-3, HAdV-7, orHAdV-55, respectively, showing lower lung viral loads and less lung Pathological changes was compared with those in unvaccinated mice. The current findings contribute to the development of a new adenovirus vaccine candidate and also advance this construction method for the generation of recombinant adenovirus vaccines. In conclusion, our recombinant trivalent vaccine rAdMHE3-h55 can provides protection against challenge with HMV-3, HAdV-7, or HAdV-55 in mice. Future work of optimizing this vaccine candidate may lead to a more effective way of preventing respiratory diseases caused by common human adenoviruses. (C) 2018 Elsevier Ltd. All rights reserved.